The secondary endpoint was a clinical status good enough to be discharged for 66 inpatients and a successful continuation therapy with the same antipsychotic agent for more than 6 months for 12 outpatients. Three groups of 26 patients each were randomized to Olanzapine, Quetiapine, or Risperidone. ...
Switching from olanzapine to aripiprazole resulted in worsening dyskinesia and new onset of dystonia. The patient's dyskinesia and dystonia improved after switching from aripiprazole to quetiapine therapy.What is new and Conclusion: There were several previous case reports on dyskinesia and dyst...
x滌絠o+Kv Z^碁ㄌ三藓 I Q啇$摏笁;鮌?κt鞲禹vy 襫x)椲畆 =橚0 苩r 4f 鏈圽"摍I騘橹{啕迺"#2饽兮 '"垦烐{墳9h桔{n {塟c异4揄 {唿F 2 舡ǚ婉臍聚汳 瑚q 叹鮪o薇ax簵 Sk
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?-A randomized, open-label study of algo- rithm-based antipsychotic treatment to patients with symp- tomatic schizophrenia in the real-world clinical setting. Psychopharmacology. 2007;195:285-295....
In the other two studies, 95 patients who were stable on prior olanzapine or quetiapine therapy were changed to long-acting injectable risperidone for 12 weeks, resulting in further symptomatic improvement for a substantial number of patients. An improvement of at least 20% in PANSS total score ...
Furthermore, 31% of patients achieved an improvement in total Positive and Negative Syndrome Scale (PANSS) scores of at least 20% when compared to baseline. In the other two studies, 95 patients who were stable on prior olanzapine or quetiapine therapy were changed to long-acting injectable ...
Switching from olanzapine to aripiprazole resulted in worsening dyskinesia and new onset of dystonia. The patient鈥檚 dyskinesia and dystonia improved after switching from aripiprazole to quetiapine therapy.What is new and Conclusion: There were several previous case reports on dyskinesia and dystonia ...
For the four most frequently used oral SGAs, the median times to all-cause discontinuation for monotherapy and polypharmacy, respectively, were 192 and 100days for aripiprazole; 222 and 86days for olanzapine; 176 and 91days for quetiapine; and 157 and 93days for risperidone. For mortality and...